Company Overview and News

 
7 Sector ETFs to Own Now | InvestorPlace

2018-04-17 investorplace
I saw an article about sector exchange-traded funds recently. While the author was talking about the 11 different S&P 500 sectors and how you can trade each of them using State Street SPDRs, it got me wondering about all the other sector ETFs to own in the marketplace.
Upvote Downvote

 
Should You Invest in the First Trust Consumer Discretionary AlphaDEX Fund (FXD)?

2018-04-09 zacks
Looking for broad exposure to the Consumer Discretionary - Broad segment of the U.S. equity market? You should consider the First Trust Consumer Discretionary AlphaDEX Fund (FXD - Free Report) , a passively managed exchange traded fund launched on 05/08/2007.
Upvote Downvote

 
ETFs to Turn Amazon's Pain Into Your Gain

2018-03-29 zacks
The latest technology rout has hit hard FANG stocks, pushing them in correction territory. After Facebook (FB - Free Report) , Alphabet (GOOGL - Free Report) and Netflix (NFLX - Free Report) , Amazon (AMZN - Free Report) has witnessed a decline of 10% from its latest peak. The technology giant saw terrible trading on Mar 28 following Axios reports, which stated that President Donald Trump is looking to target the e-commerce giant over antitrust or competition laws and is considering ways to change the tax treatment.
Upvote Downvote

 
7 ETFs to Buy With Great Ticker Symbols | InvestorPlace

2018-03-23 investorplace
According to exchange-traded fund research firm ETFGI, there are 1,876 ETFs to buy in the U.S. as of the end February. Collectively, they total $3.4 trillion in assets under management, are listed on three exchanges and are provided by 118 companies.
Upvote Downvote

 
VCR / Vanguard Consumer Discretionary ETF SECTOR FUNDS (TELECOMM SERVICES, CONSUMER DISCRETIONARY, IT) SUPPLEMENT

2018-03-23 sec.gov
coverletterxbrl497.htm - Generated by SEC Publisher for SEC Filing March 23, 2018
Upvote Downvote

 
9 ETF Winners From 9-Year Bull Run

2018-03-10 investorplace
The bull market is now nine years old, overcoming a plethora of challenges including debt crisis, government shutdown, the Middle East conflict, geopolitical tension, Greece turmoil, China’s soft landing issues, Japan’s recession, a global slowdown, Brexit, the oil price carnage, and Trump’s protectionist stance.
Upvote Downvote

 
9 ETFs Winners From 9-Year Bull Run

2018-03-09 zacks
The bull market is now nine years old, overcoming a plethora of challenges including debt crisis, government shutdown, the Middle East conflict, geopolitical tension, Greece turmoil, China’s soft landing issues, Japan’s recession, a global slowdown, Brexit, the oil price carnage, and Trump’s protectionist stance. In fact, the S&P 500 index has risen nearly 302% from the bear-market bottom of 676.53 on Mar 9, 2009.
Upvote Downvote

 
VCR / Vanguard Consumer Discretionary ETF US SECTOR FUNDS-497E

2018-03-02 sec.gov
ps5483.htm - Generated by SEC Publisher for SEC Filing Vanguard Telecommunication Services Index Fund Vanguard Consumer Discretionary Index Fund Vanguard Information Technology Index Fund Supplement to the Prospectus and Summary Prospectuses Dated December 21, 2017 On November 15, 2017, S&P Dow Jones I
Upvote Downvote

 
Stocks & ETFs That Could Win From Oscars 2018

2018-03-01 zacks
The countdown has started for the 90th Academy Awards, which will honor the best films of 2017 at the Dolby Theatre in Hollywood, on Mar 4. While the event is mainly for a creative maneuver, its huge financial impact can’t be overlooked.
Upvote Downvote

 
Amazon ETFs to Buy on Q4 Blockbuster Results

2018-02-02 zacks
After the closing bell on Thursday, online e-commerce behemoth Amazon (AMZN - Free Report) came up with blockbuster Q4 results with a huge earnings beat of 16.76% powered by big sales associated with its Alexa voice assistant and strong profits at Amazon Web Services. In fact, Amazon’s quarterly profit soared past $1 billion for the first time in its more than 20-year history. Q4 Results in Detail The company reported earnings per share of $2.
Upvote Downvote

 
VANGUARD WORLD FUND -

2018-01-26 sec.gov
world_final.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT COMPANY   Investment Company Act file number:  811-01027   Name of Registrant:   Vanguard World Fund   Address of Registrant: P.O. Box 2600 Valley Forge, PA 19482   Name and address of agent for service: Anne E.
Upvote Downvote

 
VCR / Vanguard Consumer Discretionary ETF WORLD FUND XBRL

2018-01-16 sec.gov
merged_world.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     Form N-1A   REGISTRATION STATEMENT (NO. 2-17620) UNDER THE SECURITIES ACT OF 1933 Post-Effective Amendment No. 149 and   REGISTRATION STATEMENT (NO. 811-01027) UNDER THE INVESTMENT COMPANY ACT OF 1940 Amendment No. 149     VANGUARD WORLD FUND (Exact Name of Registrant as Specified in Declaration of Trust)   P.
Upvote Downvote

 
VCR / Vanguard Consumer Discretionary ETF VANGUARD U.S. GROWTH FUND SUMMARY

2017-12-28 sec.gov
usgrowthfundsp0231220172.htm - Generated by SEC Publisher for SEC Filing Vanguard U.S. Growth Fund   Summary Prospectus     December 21, 2017     Investor Shares & Admiral™ Shares   Vanguard U.S. Growth Fund Investor Shares (VWUSX) Vanguard U.S. Growth Fund Admiral Shares (VWUAX)         The Fund’s statutory Prospectus and Statement of Additional Information dated December 21, 2017, as may be amended or supplemented, are incorporated into and made part of this Summary Prospectus by reference.
Upvote Downvote

 
VCR / Vanguard Consumer Discretionary ETF INTERNATIONAL GROWTH SUMMARY

2017-12-28 sec.gov
internationalgrowthsp0811220.htm - Generated by SEC Publisher for SEC Filing Vanguard International Growth Fund   Summary Prospectus     December 21, 2017     Investor Shares & Admiral™ Shares   Vanguard International Growth Fund Investor Shares (VWIGX) Vanguard International Growth Fund Admiral Shares (VWILX)         The Fund’s statutory Prospectus and Statement of Additional Information dated December 21, 2017, as may be amended or supplemented, are incorporated into and made part of this Summ
Upvote Downvote

 
VCR / Vanguard Consumer Discretionary ETF 497J-WORLD FUND-GLOBAL WELLINGTON AND GLOBAL WELLESLEY

2017-12-26 sec.gov
j-1226.htm - Generated by SEC Publisher for SEC Filing December 26, 2017       U.S. Securities & Exchange Commission 100 F Street, NE Washington, DC 20549     Re: Vanguard World Fund (the "Trust")   File No. 2-17620     Commissioners:   Pursuant to Rule 497(j) under the Securities Act of 1933, this letter serves as certification that the Prospectus and Statement of Additional Information with respect to the above-referenced Trust do not differ from that filed in the most recent post-effective am
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 92204A504